Cargando…
Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors
The Spike receptor binding domain (S-RBD) from SARS-CoV-2, a crucial protein for the entrance of the virus into target cells is known to cause infection by binding to a cell surface protein. Hence, reckoning therapeutics for the S-RBD of SARS-CoV-2 may address a significant way to target viral entry...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264305/ https://www.ncbi.nlm.nih.gov/pubmed/34273770 http://dx.doi.org/10.1016/j.compbiomed.2021.104631 |
_version_ | 1783719525045239808 |
---|---|
author | Singh, Rahul Bhardwaj, Vijay Kumar Sharma, Jatin Kumar, Dinesh Purohit, Rituraj |
author_facet | Singh, Rahul Bhardwaj, Vijay Kumar Sharma, Jatin Kumar, Dinesh Purohit, Rituraj |
author_sort | Singh, Rahul |
collection | PubMed |
description | The Spike receptor binding domain (S-RBD) from SARS-CoV-2, a crucial protein for the entrance of the virus into target cells is known to cause infection by binding to a cell surface protein. Hence, reckoning therapeutics for the S-RBD of SARS-CoV-2 may address a significant way to target viral entry into the host cells. Herein, through in-silico approaches (Molecular docking, molecular dynamics (MD) simulations, and end-state thermodynamics), we aimed to screen natural molecules from different plants for their ability to inhibit S-RBD of SARS-CoV-2. We prioritized the best interacting molecules (Diacetylcurcumin and Dicaffeoylquinic acid) by analysis of protein-ligand interactions and subjected them for long-term MD simulations. We found that Dicaffeoylquinic acid interacted prominently with essential residues (Lys417, Gln493, Tyr489, Phe456, Tyr473, and Glu484) of S-RBD. These residues are involved in interactions between S-RBD and ACE2 and could inhibit the viral entry into the host cells. The in-silico analyses indicated that Dicaffeoylquinic acid and Diacetylcurcumin might have the potential to act as inhibitors of SARS-CoV-2 S-RBD. The present study warrants further in-vitro and in-vivo studies of Dicaffeoylquinic acid and Diacetylcurcumin for validation and acceptance of their inhibitory potential against S-RBD of SARS-CoV-2. |
format | Online Article Text |
id | pubmed-8264305 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82643052021-07-08 Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors Singh, Rahul Bhardwaj, Vijay Kumar Sharma, Jatin Kumar, Dinesh Purohit, Rituraj Comput Biol Med Article The Spike receptor binding domain (S-RBD) from SARS-CoV-2, a crucial protein for the entrance of the virus into target cells is known to cause infection by binding to a cell surface protein. Hence, reckoning therapeutics for the S-RBD of SARS-CoV-2 may address a significant way to target viral entry into the host cells. Herein, through in-silico approaches (Molecular docking, molecular dynamics (MD) simulations, and end-state thermodynamics), we aimed to screen natural molecules from different plants for their ability to inhibit S-RBD of SARS-CoV-2. We prioritized the best interacting molecules (Diacetylcurcumin and Dicaffeoylquinic acid) by analysis of protein-ligand interactions and subjected them for long-term MD simulations. We found that Dicaffeoylquinic acid interacted prominently with essential residues (Lys417, Gln493, Tyr489, Phe456, Tyr473, and Glu484) of S-RBD. These residues are involved in interactions between S-RBD and ACE2 and could inhibit the viral entry into the host cells. The in-silico analyses indicated that Dicaffeoylquinic acid and Diacetylcurcumin might have the potential to act as inhibitors of SARS-CoV-2 S-RBD. The present study warrants further in-vitro and in-vivo studies of Dicaffeoylquinic acid and Diacetylcurcumin for validation and acceptance of their inhibitory potential against S-RBD of SARS-CoV-2. Elsevier Ltd. 2021-09 2021-07-08 /pmc/articles/PMC8264305/ /pubmed/34273770 http://dx.doi.org/10.1016/j.compbiomed.2021.104631 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Singh, Rahul Bhardwaj, Vijay Kumar Sharma, Jatin Kumar, Dinesh Purohit, Rituraj Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors |
title | Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors |
title_full | Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors |
title_fullStr | Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors |
title_full_unstemmed | Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors |
title_short | Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors |
title_sort | identification of potential plant bioactive as sars-cov-2 spike protein and human ace2 fusion inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264305/ https://www.ncbi.nlm.nih.gov/pubmed/34273770 http://dx.doi.org/10.1016/j.compbiomed.2021.104631 |
work_keys_str_mv | AT singhrahul identificationofpotentialplantbioactiveassarscov2spikeproteinandhumanace2fusioninhibitors AT bhardwajvijaykumar identificationofpotentialplantbioactiveassarscov2spikeproteinandhumanace2fusioninhibitors AT sharmajatin identificationofpotentialplantbioactiveassarscov2spikeproteinandhumanace2fusioninhibitors AT kumardinesh identificationofpotentialplantbioactiveassarscov2spikeproteinandhumanace2fusioninhibitors AT purohitrituraj identificationofpotentialplantbioactiveassarscov2spikeproteinandhumanace2fusioninhibitors |